-
Mashup Score: 5
Here, we summarize presentations from ASH 2023 by Russel.1, Othman.2,4, Loo.3, and Gui.5,6 discussing the prognostic utility of measurable residual disease in patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
Can measurable residual disease be used to guide treatment decisions? Does pretransplant measurable residual disease status affect transplant outcomes? 👉Read our summary of the latest insights from #ASH2023 on MRD to find out: https://t.co/mIRRvkHXIn #leusm #AMLsm https://t.co/JD6eiPoRJr